Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Double-blind Placebo Controlled Multicenter Clinical Trial of Efficacy and Safety of Ingavirin® Capsules 30mg, in Daily Dose 60mg for the Treatment of Influenza and Other Acute Respiratory Viral Infections at Patients 13-18 y.o.

NCT03206346 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT03206346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03206346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Double-blind Placebo Controlled Multicenter Clinical Trial of Efficacy and Safety of Ingavirin® Capsules 30mg, in Daily Dose 60mg for the Treatment of Influenza and Other Acute Respiratory Viral Infections at Patients 13-18 y.o.
Lead sponsor
Valenta Pharm JSC
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2012
Completion date
August 31, 2013
Enrollment
161 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory infection, common cold, influenza, human, viral infection